MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology
- 19 December 2010
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 102 (3), 522-529
- https://doi.org/10.1111/j.1349-7006.2010.01816.x
Abstract
A new diagnostic marker for urothelial carcinoma (UC) is needed to avoid painful cystoscopy during the initial diagnosis and follow-up period. However, the current urine markers are useless because of the low sensitivities and specificities for UC detection. MiR-96 and miR-183 were differentially upregulated microRNA in our previous microRNA screening for UC. The expression levels of miR-96 and miR-183 in the urine samples were significantly higher in 100 UC than in healthy controls (miR-96, P = 0.0059; and miR-183, P = 0.0044). The receiver-operating characteristic curve analyses demonstrated that each microRNA had good sensitivity and specificity for distinguishing UC patients from non-UC patients (miR-96, 71.0% and 89.2%; and miR-183, 74.0% and 77.3%). Our cohort included 78 UC patients who had undergone urinary cytology. MiR-96 was positively detected in 27 of 44 patients who had had a "negative" urinary cytology diagnosis. We combined the miR-96 detection data with the urinary cytology data, and diagnosed 61 of 78 cases as UC; sensitivity rose from 43.6% to 78.2%. We found significant stepwise increases in miR-96 and miR-183 expression with advancing tumor grade (miR-96, P = 0.0057; and miR-183, P = 0.0036) and pathological stage (miR-96, P = 0.0332; and miR-183, P = 0.0117). The expression levels of the microRNA were significantly lower in urine collected after surgery (miR-96, P = 0.0241; and miR-183, P = 0.0045). In conclusion, miR-96 and miR-183 in urine are promising tumor markers for UC. In particular, miR-96 may be a good diagnostic marker in combination with urinary cytology. (Cancer Sci 2011; 102: 522-529)This publication has 38 references indexed in Scilit:
- miR-183 inhibits TGF-β1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cellsBMC Cancer, 2010
- Identification of differentially expressed microRNAs in human male breast cancerBMC Cancer, 2010
- New insights into the evolution of subtilisin-like serine protease genes in PezizomycotinaBMC Evolutionary Biology, 2010
- miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancerBritish Journal of Cancer, 2010
- Definition of microRNAs That Repress Expression of the Tumor Suppressor Gene FOXO1 in Endometrial CancerCancer Research, 2010
- Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative statesBMC Cancer, 2009
- Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer CellsJournal of Biological Chemistry, 2009
- The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platformGynecologic Oncology, 2009
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006